Published in J Virol on October 01, 1998
A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A (1998) 6.76
Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J Virol (1999) 4.57
The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J (2000) 3.52
The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. Genes Dev (2002) 2.59
Rta of murine gammaherpesvirus 68 reactivates the complete lytic cycle from latency. J Virol (2000) 2.35
An HIV feedback resistor: auto-regulatory circuit deactivator and noise buffer. PLoS Biol (2007) 2.17
NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol (2003) 2.15
Octamer-binding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated herpesvirus ORF50/Lyta gene expression. J Virol (2001) 2.13
Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol (2004) 2.11
Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol (2001) 2.07
The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathog (2010) 1.97
Transcription program of murine gammaherpesvirus 68. J Virol (2003) 1.96
Characterization of gammaherpesvirus 68 gene 50 transcription. J Virol (2000) 1.84
EBV noncoding RNA binds nascent RNA to drive host PAX5 to viral DNA. Cell (2015) 1.78
Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol (2000) 1.77
Transcriptional regulation of the Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor gene. J Virol (2000) 1.71
Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe (2010) 1.70
Role of the epstein-barr virus RTA protein in activation of distinct classes of viral lytic cycle genes. J Virol (1999) 1.66
Function of Rta is essential for lytic replication of murine gammaherpesvirus 68. J Virol (2001) 1.61
Kaposi's sarcoma-associated herpesvirus K-bZIP is a coregulator of K-Rta: physical association and promoter-dependent transcriptional repression. J Virol (2003) 1.60
MCAF1 and synergistic activation of the transcription of Epstein-Barr virus lytic genes by Rta and Zta. Nucleic Acids Res (2010) 1.52
Kaposi's sarcoma-associated herpesvirus K-bZIP protein is phosphorylated by cyclin-dependent kinases. J Virol (2001) 1.51
Early activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, and MTA promoters by the tetradecanoyl phorbol acetate-induced AP1 pathway. J Virol (2004) 1.51
Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites. J Virol (2001) 1.47
Lytic but not latent replication of epstein-barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins. J Virol (2000) 1.47
Disruption of gammaherpesvirus 68 gene 50 demonstrates that Rta is essential for virus replication. J Virol (2003) 1.39
ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog (2007) 1.33
Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus. PLoS Pathog (2007) 1.32
Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation. Nucleic Acids Res (2000) 1.28
Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J Virol (2001) 1.27
ZEB negatively regulates the lytic-switch BZLF1 gene promoter of Epstein-Barr virus. J Virol (2003) 1.25
Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J Virol (2002) 1.23
The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction. J Virol (1999) 1.20
The BFRF1 gene of Epstein-Barr virus encodes a novel protein. J Virol (2000) 1.20
The DNA architectural protein HMGB1 displays two distinct modes of action that promote enhanceosome assembly. Mol Cell Biol (2002) 1.20
An Sp1 response element in the Kaposi's sarcoma-associated herpesvirus open reading frame 50 promoter mediates lytic cycle induction by butyrate. J Virol (2005) 1.19
Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner. J Virol (2010) 1.17
ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells. J Virol (2007) 1.14
A gammaherpesvirus 68 gene 50 null mutant establishes long-term latency in the lung but fails to vaccinate against a wild-type virus challenge. J Virol (2006) 1.11
The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1. J Virol (2004) 1.10
Phosphorylation of Epstein-Barr virus ZEBRA protein at its casein kinase 2 sites mediates its ability to repress activation of a viral lytic cycle late gene by Rta. J Virol (2004) 1.09
Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression. J Virol (2004) 1.08
A functionally distinct TATA box required for late progression through the Epstein-Barr virus life cycle. J Virol (1998) 1.08
Epstein-Barr virus immediate-early protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation. J Virol (2001) 1.07
Marked variation in response of consensus binding elements for the Rta protein of Epstein-Barr virus. J Virol (2005) 1.05
Alternatively initiated gene 50/RTA transcripts expressed during murine and human gammaherpesvirus reactivation from latency. J Virol (2008) 1.05
Matrix metalloproteinase 9 is induced by the Epstein-Barr virus BZLF1 transactivator. Clin Exp Metastasis (1999) 1.03
The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli. J Virol (2012) 1.03
Disruption of Epstein-Barr virus latency in the absence of phosphorylation of ZEBRA by protein kinase C. J Virol (2002) 1.03
Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells. J Virol (2008) 1.02
Ex vivo stimulation of B cells latently infected with gammaherpesvirus 68 triggers reactivation from latency. J Virol (2005) 1.00
Sumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase. J Virol (2010) 0.99
Role of the TSG101 gene in Epstein-Barr virus late gene transcription. J Virol (2006) 0.98
Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication. J Virol (2012) 0.95
Regulation of autophagic activation by Rta of Epstein-Barr virus via the extracellular signal-regulated kinase pathway. J Virol (2014) 0.95
Herpesvirus saimiri open reading frame 50 (Rta) protein reactivates the lytic replication cycle in a persistently infected A549 cell line. J Virol (2001) 0.95
Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J Virol (2002) 0.95
Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta. J Virol (2004) 0.93
MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1. J Virol (2014) 0.91
The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1. PLoS Pathog (2012) 0.89
Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency. J Virol (2011) 0.88
Differentiation-Dependent KLF4 Expression Promotes Lytic Epstein-Barr Virus Infection in Epithelial Cells. PLoS Pathog (2015) 0.87
Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle. J Virol (2011) 0.87
Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 RTA reactivates murine gammaherpesvirus 68 from latency. J Virol (2005) 0.87
Viral response to chemotherapy in endemic burkitt lymphoma. Clin Cancer Res (2010) 0.87
Reactive oxygen species mediate Epstein-Barr virus reactivation by N-methyl-N'-nitro-N-nitrosoguanidine. PLoS One (2013) 0.87
Negative autoregulation of Epstein-Barr virus (EBV) replicative gene expression by EBV SM protein. J Virol (2009) 0.86
The Epstein-Barr virus BRRF1 protein, Na, induces lytic infection in a TRAF2- and p53-dependent manner. J Virol (2011) 0.86
Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus. J Virol (2009) 0.86
Phosphoacceptor site S173 in the regulatory domain of Epstein-Barr Virus ZEBRA protein is required for lytic DNA replication but not for activation of viral early genes. J Virol (2007) 0.86
RTA promoter demethylation and histone acetylation regulation of murine gammaherpesvirus 68 reactivation. PLoS One (2009) 0.85
Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody. J Virol (2001) 0.85
Essential role of Rta in lytic DNA replication of Epstein-Barr virus. J Virol (2012) 0.85
Sequential use of paraformaldehyde and methanol as optimal conditions for the direct quantification of ZEBRA and rta antigens by flow cytometry. Clin Diagn Lab Immunol (2000) 0.85
The Epstein-Barr virus LF2 protein inhibits viral replication. J Virol (2008) 0.85
Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta. Virology (2010) 0.85
The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins. J Virol (2010) 0.84
Characterization and intracellular trafficking of Epstein-Barr virus BBLF1, a protein involved in virion maturation. J Virol (2012) 0.84
The C-mer gene is induced by Epstein-Barr virus immediate-early protein BRLF1. J Virol (2004) 0.83
Characterization of the uracil-DNA glycosylase activity of Epstein-Barr virus BKRF3 and its role in lytic viral DNA replication. J Virol (2006) 0.83
Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters. J Virol (2014) 0.83
Epstein-Barr virus (EBV) Rta-mediated EBV and Kaposi's sarcoma-associated herpesvirus lytic reactivations in 293 cells. PLoS One (2011) 0.82
Prospects of a novel vaccination strategy for human gamma-herpesviruses. Immunol Res (2010) 0.82
Epstein-Barr virus LF2 protein regulates viral replication by altering Rta subcellular localization. J Virol (2010) 0.82
Uracil DNA glycosylase BKRF3 contributes to Epstein-Barr virus DNA replication through physical interactions with proteins in viral DNA replication complex. J Virol (2014) 0.81
Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids. J Virol (2014) 0.81
Identification of alternative transcripts encoding the essential murine gammaherpesvirus lytic transactivator RTA. J Virol (2014) 0.80
Latency of Epstein-Barr virus is disrupted by gain-of-function mutant cellular AP-1 proteins that preferentially bind methylated DNA. Proc Natl Acad Sci U S A (2013) 0.80
Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoter. J Virol (2007) 0.80
Sequence analysis of the Epstein-Barr virus (EBV) BRLF1 gene in nasopharyngeal and gastric carcinomas. Virol J (2010) 0.80
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA). Lancet (1964) 9.32
Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature (1978) 9.25
Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A (1985) 8.19
Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J (1986) 6.82
A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A (1998) 6.76
Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol (1989) 5.67
A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol (1988) 5.28
trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol (1986) 5.25
Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine (1975) 4.68
Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol (1987) 4.12
Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol (1990) 4.09
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology (1979) 4.02
Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells. Proc Natl Acad Sci U S A (1983) 3.71
Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators. EMBO J (1989) 3.23
Identification and characterization of an RNA molecule that copurifies with RNase P activity from HeLa cells. Genes Dev (1989) 3.16
An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J Virol (1990) 3.13
Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci U S A (1996) 3.13
The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J Virol (1989) 3.11
Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol (1990) 3.09
Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. J Virol (1983) 3.06
The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol (1989) 2.98
Transfection of a rearranged viral DNA fragment, WZhet, stably converts latent Epstein-Barr viral infection to productive infection in lymphoid cells. Proc Natl Acad Sci U S A (1987) 2.96
Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays. J Virol (1995) 2.63
The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J Virol (1990) 2.49
Pathways of activation of the Epstein-Barr virus productive cycle. J Virol (1991) 2.42
Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res (1993) 2.38
The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R. J Virol (1989) 2.20
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol (1994) 2.12
A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus. EMBO J (1993) 1.96
cis-acting elements in the lytic origin of DNA replication of Epstein-Barr virus. J Virol (1993) 1.80
Epstein-Barr virus induction by a serum factor. I. Induction and cooperation with additional inducers. Virology (1982) 1.80
The Epstein-Barr virus (EBV) early promoter DR contains a cis-acting element responsive to the EBV transactivator EB1 and an enhancer with constitutive and inducible activities. J Virol (1989) 1.79
Heterogeneity of Epstein-Barr virus originating from P3HR-1 cells. I. Studies on EBNA induction. Int J Cancer (1977) 1.70
Characterization of the DNA-binding site repertoire for the Epstein-Barr virus transcription factor R. Nucleic Acids Res (1994) 1.58
The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B. Mol Cell Biol (1994) 1.54
Characterization of a bovine herpesvirus 4 immediate-early RNA encoding a homolog of the Epstein-Barr virus R transactivator. J Virol (1993) 1.52
The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor. J Virol (1992) 1.47
Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras. J Virol (1996) 1.47
Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication. J Virol (1996) 1.44
Regulation of the herpesvirus saimiri (HVS) delayed-early 110-kilodalton promoter by HVS immediate-early gene products and a homolog of the Epstein-Barr virus R trans activator. J Virol (1991) 1.44
Two 21-kilodalton components of the Epstein-Barr virus capsid antigen complex and their relationship to ZEBRA-associated protein p21 (ZAP21). J Virol (1996) 1.41
Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome. J Gen Virol (1996) 1.35
Alteration of a single serine in the basic domain of the Epstein-Barr virus ZEBRA protein separates its functions of transcriptional activation and disruption of latency. J Virol (1997) 1.35
Polymorphisms of the region of the Epstein-Barr virus genome which disrupts latency. Virology (1988) 1.33
Transfer and expression of plasmids containing human cytomegalovirus immediate-early gene 1 promoter-enhancer sequences in eukaryotic and prokaryotic cells. Biotechnol Appl Biochem (1988) 1.32
Late gene expression from the Epstein-Barr virus BcLF1 and BFRF3 promoters does not require DNA replication in cis. J Virol (1997) 1.30
Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. Virology (1991) 1.29
Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F. J Virol (1996) 1.27
Strain variation in Epstein-Barr virus immediate early genes. Virology (1993) 1.23
Concatameric replication of Epstein-Barr virus: structure of the termini in virus-producer and newly transformed cell lines. J Virol (1990) 1.21
The Zif268 cellular transcription factor activates expression of the Epstein-Barr virus immediate-early BRLF1 promoter. J Virol (1995) 1.15
Functional antagonism between the retinoic acid receptor and the viral transactivator BZLF1 is mediated by protein-protein interactions. Proc Natl Acad Sci U S A (1995) 1.11
Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc Natl Acad Sci U S A (1993) 1.07
The cellular YY1 transcription factor binds a cis-acting, negatively regulating element in the Epstein-Barr virus BRLF1 promoter. J Virol (1997) 1.06
Different activation of Epstein-Barr virus immediate-early and early genes in Burkitt lymphoma cells and lymphoblastoid cell lines. J Virol (1994) 1.05
Viral proteins associated with the Epstein-Barr virus transactivator, ZEBRA. Proc Natl Acad Sci U S A (1992) 1.04
The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent. J Virol (1990) 0.95
The bZip dimerization domain of the Epstein-Barr virus BZLF1 (Z) protein mediates lymphoid-specific negative regulation. Virology (1997) 0.89
EBV-immortalized isogenic human B-cell clones exhibit differences in DNA-protein complex formation on the BZLF1 and BRLF1 promoter regions among latent, lytic and TPA-activated cell lines. Virus Res (1994) 0.86
Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A (1973) 12.70
Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci U S A (1972) 8.53
Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A (1985) 8.19
Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A (1981) 7.43
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 6.84
A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A (1998) 6.76
Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. Proc Natl Acad Sci U S A (1974) 5.54
Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye. J Virol (1982) 4.65
Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol (1997) 4.45
New Epstein-Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma. Nature (1982) 4.43
Stable expression in mouse cells of nuclear neoantigen after transfer of a 3.4-megadalton cloned fragment of Epstein-Barr virus DNA. Proc Natl Acad Sci U S A (1982) 4.23
Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol (1999) 4.20
Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol (1987) 4.12
Nucleic acid spot hybridization: rapid quantitative screening of lymphoid cell lines for Epstein-Barr viral DNA. Proc Natl Acad Sci U S A (1980) 4.10
Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med (1998) 3.75
Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells. Proc Natl Acad Sci U S A (1983) 3.71
Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61
Epstein-Barr virus with heterogeneous DNA disrupts latency. J Virol (1984) 3.51
Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol (2000) 3.50
Prolonged oropharyngeal excretion of Epstein-Barr virus after infectious mononucleosis. N Engl J Med (1973) 3.33
Use of personal medical records for research purposes. BMJ (1994) 3.29
Establishment of cell lines from normal adult human blood leukocytes by exposure to Epstein-Barr virus and neutralization by human sera with Epstein-Barr virus antibody. Proc Soc Exp Biol Med (1971) 3.17
Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus. Proc Natl Acad Sci U S A (1973) 3.14
Transfection of a rearranged viral DNA fragment, WZhet, stably converts latent Epstein-Barr viral infection to productive infection in lymphoid cells. Proc Natl Acad Sci U S A (1987) 2.96
Efficiency of transformation of lymphocytes by Epstein-Barr virus. Virology (1977) 2.94
Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J Virol (1989) 2.86
Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. Nature (1990) 2.80
Polyadenylylated nuclear RNA encoded by Kaposi sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A (1996) 2.76
Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet (2001) 2.76
Two Epstein-Barr viral nuclear neoantigens distinguished by gene transfer, serology, and chromosome binding. Proc Natl Acad Sci U S A (1983) 2.68
Hantavirus pulmonary syndrome: the first 100 US cases. J Infect Dis (1996) 2.64
Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J Infect Dis (1997) 2.60
Epstein-Barr viral antigen in single cell clones of two human leukocytic lines. J Virol (1970) 2.59
Major EB virus-specific cytoplasmic transcripts in a cellular clone of the HR-1 Burkitt lymphoma line during latency and after induction of viral replicative cycle by phorbol esters. Virology (1983) 2.54
Systemic and mucosal humoral responses to Helicobacter pylori in gastric cancer. Gut (1993) 2.47
Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial. BMJ (2012) 2.33
Identification of Epstein-Barr nuclear antigen polypeptide in mouse and monkey cells after gene transfer with a cloned 2.9-kilobase-pair subfragment of the genome. Proc Natl Acad Sci U S A (1984) 2.32
Novel nuclear antigens recognized by human sera in lymphocytes latently infected by Epstein-Barr virus. Virology (1987) 2.32
Kaposi's sarcoma-associated herpesvirus encodes a bZIP protein with homology to BZLF1 of Epstein-Barr virus. J Virol (1999) 2.24
Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis (1996) 2.23
Biological properties and viral surface antigens of Burkitt lymphoma- and mononucleosis- derived strains of Epstein-Barr virus released from transformed marmoset cells. J Virol (1976) 2.22
Acute cardiac events temporally related to cocaine abuse. N Engl J Med (1986) 2.18
Genome of a mononucleosis Epstein-Barr virus contains DNA fragments previously regarded to be unique to Burkitt's lymphoma isolates. Cell (1981) 2.17
Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc Natl Acad Sci U S A (1988) 2.12
Comparison of the yield of infectious virus from clones of human and simian lymphoblastoid lines transformed by Epstein-Barr virus. J Exp Med (1973) 2.11
Recovery of Epstein-Barr virus from nonproducer neonatal human lymphoid cell transformants. Virology (1979) 2.09
Use of cloned probes to detect Epstein-Barr viral DNA in tissues of patients with neoplastic and lymphoproliferative diseases. J Infect Dis (1983) 1.99
Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J Infect Dis (1989) 1.99
Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum antibody responses, demonstration of viral DNA, and characterization of viruses. J Exp Med (1977) 1.90
Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis (1985) 1.88
Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet (1998) 1.83
A randomized trial to evaluate the effectiveness of dietary advice by practice nurses in lowering diet-related coronary heart disease risk. Br J Gen Pract (1997) 1.81
Trypsinized placental cell cultures for the propagation of viruses and as "feeder layers". J Virol (1970) 1.77
Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev (1999) 1.76
Establishment of lines from normal human blood leukocytes by co-cultivation with a leukocyte line derived from a leukemic child. Proc Soc Exp Biol Med (1969) 1.76
P3HR-1 Epstein-Barr virus with heterogeneous DNA is an independent replicon maintained by cell-to-cell spread. J Virol (1985) 1.73
The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation (1988) 1.72
Vaccinia virus replication and cytopathic effect in cultures in phytohemagglutinin-treated human peripheral blood leukocytes. J Virol (1968) 1.68
Role of the epstein-barr virus RTA protein in activation of distinct classes of viral lytic cycle genes. J Virol (1999) 1.66
Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol (1990) 1.62
Diffuse polyclonal B-cell lymphoma during primary infection with Epstein-Barr virus. N Engl J Med (1980) 1.61
Analysis of the genomic sequence for the autosomal dominant polycystic kidney disease (PKD1) gene predicts the presence of a leucine-rich repeat. The American PKD1 Consortium (APKD1 Consortium). Hum Mol Genet (1995) 1.59
Expression in COS-1 cells of Epstein-Barr virus nuclear antigen from a complete gene and a deleted gene. J Virol (1984) 1.57
Resolution of invasive central nervous system aspergillosis in a transplant recipient. Bone Marrow Transplant (1997) 1.57
Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet (1974) 1.56
ZEBRA and a Fos-GCN4 chimeric protein differ in their DNA-binding specificities for sites in the Epstein-Barr virus BZLF1 promoter. J Virol (1991) 1.56
Transcriptional synergy by the Epstein-Barr virus transactivator ZEBRA. J Virol (1992) 1.55
The oncogenicity of Epstein-Barr virus. J Infect Dis (1974) 1.55
Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia (2000) 1.54
Positron emission tomography in Alzheimer's disease. Neurology (1986) 1.52
Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS. Lancet (1986) 1.51
Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. Ann Intern Med (1986) 1.48
Expression of Epstein-Barr viral early antigen in monolayer tissue cultures after transfection with viral DNA and DNA fragments. J Virol (1981) 1.48
Structure of the bacteriophage lambda cohesive end site: location of the sites of terminase binding (cosB) and nicking (cosN). Gene (1983) 1.48
Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites. J Virol (2001) 1.47
Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras. J Virol (1996) 1.47
Identification, expression, and immunogenicity of Kaposi's sarcoma-associated herpesvirus-encoded small viral capsid antigen. J Virol (1997) 1.47
The epidemiology of St. Louis encephalitis in Houston, Texas, 1964. Am J Epidemiol (1967) 1.46
Sequences of the Epstein-Barr Virus (EBV) large internal repeat form the center of a 16-kilobase-pair palindrome of EBV (P3HR-1) heterogeneous DNA. J Virol (1987) 1.45
Expression of the BZLF1 latency-disrupting gene differs in standard and defective Epstein-Barr viruses. J Virol (1989) 1.45
Renal extraction of gentamicin in anesthetized dogs. Antimicrob Agents Chemother (1976) 1.45
Minimizing ports to improve laparoscopic cholecystectomy. Surg Endosc (2000) 1.44
Emergency department use of aspirin in patients with possible acute myocardial infarction. Ann Intern Med (1997) 1.42
Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-alpha plays a critical role in maintaining secondary immunity in the absence of IFN-gamma. J Immunol (1998) 1.42
Mononucleosis with heterophil antibodies and EB virus infection. Acquisition by an elderly patient in hospital. Am J Med (1971) 1.41
Palindromic structure and polypeptide expression of 36 kilobase pairs of heterogeneous Epstein-Barr virus (P3HR-1) DNA. J Virol (1986) 1.41